UC Davis’ Venture Catalyst recruits Science Exchange’s outsourced R&D marketplace

handshake / shaking hands
The startup support organization joins more than 30 enterprises that use Science Exchange to select and manage outsourced R&D services. (daizuoxin/iStock/Getty Images)

In a new collaboration, Science Exchange will offer its outsourced R&D marketplace to startups supported by the Venture Catalyst arm under the University of California, Davis.

To be specific, those participating in the Smart Toolkit for Accelerated Research Translation (START) program will gain immediate access to Science Exchange’s services.

Venture Catalyst helps the development of new ventures spun out from UC Davis’ research. Like many other similar research-to-business incubator programs, Venture Catalyst provides a suite of supports for entrepreneurs. Such offerings listed within the START program include patent, government grant application, banking, market intelligence and business development.


Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

RELATED: Science Exchange signs University of California life science startup hub

“We anticipate that working with Science Exchange through the START Program will enable us to commercially advance the discoveries made by Venture Catalyst-supported startups and early-stage companies, in areas as diverse as biomedical and life sciences, agriculture and animal health, and physical sciences and engineering,” said Dushyant Pathak, executive director of Venture Catalyst, in a statement.

The startup support organization joins more than 30 enterprises, including most of the top 20 biopharma companies, that use Science Exchange to select and manage outsourced R&D services from a network of more than 2,500 prequalified providers, according to Science Exchange.

The new collaboration came just a few months after QB3, the University of California entrepreneurship hub focused on life sciences, tapped Science Exchange’s platform for companies under its wings.

Suggested Articles

Bayer CEO Werner Baumann stressed “less and less trust in society" for technology advances as a hurdle for pharma companies working on gene editing.

As GlaxoSmithKline looks to start a 23andMe-partnered test this year, the Big Pharma is increasingly looking to tech for its R&D.

LabCorp has unveiled a new suite of cell and gene therapy development offerings from Covance as it looks to get into this burgeoning area.